Researching IPF after her late husband's diagnosis meant learning many new acronyms and abbreviations, says guest writer.

Inhaled lipid nanoparticles loaded with two medicines reduced IPF lung stiffness and fibrosis in mice, outperforming an ...

MUMBAI – Music composer duo Salim-Sulaiman have released their new track ‘Shringaar’ as a tribute to the late tabla maestro Zakir Hussain, with fellow composer and vocalist Shankar Mahadevan lending ...

FDA lifts clinical hold following review of Company’s Complete Response submission. Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites. Early data suggests ...

Zakir Hussain, the renowned tabla virtuoso and percussionist who was instrumental in spreading the sound and splendor of classical Indian music worldwide, will be celebrated by friends and ...

For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), according to a study presented at CHEST 2025, the annual meeting of the ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF). This is the first new therapy in more than 10 years to be approved for ...

Tivardi Therapeutics (NASDAQ:TVRD) is down ~85% in Monday trading after reporting that preliminary results from a phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis showed significantly higher ...

Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...

Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...